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Brain-derived neurotrophic factor (BDNF) influences the differen-
tiation, plasticity, and survival of central neurons and likewise,
affects the development of the neuromuscular system. Besides its
neuronal origin, BDNF is also a member of the myokine family.
However, the role of skeletal muscle-derived BDNF in regulating
neuromuscular physiology in vivo remains unclear. Using gain-
and loss-of-function animal models, we show that muscle-specific
ablation of BDNF shifts the proportion of muscle fibers from type
IIB to IIX, concomitant with elevated slow muscle-type gene
expression. Furthermore, BDNF deletion reduces motor end plate
volume without affecting neuromuscular junction (NMJ) integrity.
These morphological changes are associated with slow muscle
function and a greater resistance to contraction-induced fatigue.
Conversely, BDNF overexpression promotes a fast muscle-type
gene program and elevates glycolytic fiber number. These findings
indicate that BDNF is required for fiber-type specification and
provide insights into its potential modulation as a therapeutic
target in muscle diseases.
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Neurotrophins (NTs) are members of a subfamily of struc-turally related trophic factors that regulate the differentia-
tion, survival, and function of neuronal cells by modulating the
p75NTR receptor and members of the Trk family of receptor ty-
rosine kinases (1, 2). Besides the central nervous system, skeletal
muscle is an abundant source of trophic factors during develop-
ment (3, 4). In particular, NTs can be released from muscle fibers,
acting on the nerve terminals of motor neurons (5, 6), in addition
to using retrograde routes to be transported to the cell body (7, 8).
Inactivation or overexpression of NTs in mouse models dem-
onstrates their broad involvement in neuromuscular physiology.
For instance, chronic deprivation of the nerve growth factor
leads to muscular dystrophy (9). Deficiency in NT-3 or its re-
ceptor TrkC decreases proprioceptive afferents and muscle
spindles, resulting in severe movement defects (10, 11). Lack of
NT-4/5 induces the disassembly of postsynaptic acetylcholine
receptor (AChR) clusters in association with neurotransmission
failure and decreased fatigue resistance (12).
Similar to these NT family members, the brain-derived neu-
rotrophic factor (BDNF) also exerts diverse roles in the neuro-
muscular system. For example, BDNF regulates agrin-induced
AChR clustering in cultured myotubes (13). Moreover, pre-
cursor and mature forms of BDNF influence the survival and
innervation pattern of developing motor neurons by modulating
both p75NTR and TrkB receptors (8, 14). Accordingly, mice
heterozygous for TrkB display altered neuromuscular junction
(NMJ) structure and function as well as muscle weakness and
sarcopenia (6, 15). In contrast to BDNF of neuronal origin, the
role of BDNF in muscle function is much less studied, in part
due to controversial BDNF detection in this tissue (16). There is,
however, evidence that BDNF is a contraction-induced myokine
likely involved in autocrine and/or paracrine regulation of mus-
cle fat metabolism (17). Moreover, specific loss of BDNF within
the satellite cell niche affects early stages of the regenerative
process after muscle cardiotoxin injury (18). However, no study
to date has comprehensively investigated the potential contri-
bution of skeletal muscle-derived BDNF to both muscle and
NMJ physiology in the postnatal mouse in vivo.
Using functional, cellular, and molecular approaches, we show
that mice lacking BDNF specifically in striated muscle fibers do
not exhibit any developmental neuromuscular or metabolic defi-
cits. Intriguingly, we discovered that loss of BDNF within muscle
fibers induces structural and functional remodeling of the NMJ
toward a slower phenotype. In line, our data indicate that muscle
BDNF loss or gain of function is sufficient to decrease or increase,
respectively, the proportion of types IIB and IIX muscle fibers
along with a broad range of oxidative and glycolytic marker genes.
Results
BDNF Muscle Knockout Mice Show Altered Spontaneous Gait Behavior
and Locomotion. To restrict the Cre-induced recombination of the
Bdnf floxed allele to skeletal muscle cells, we used the human
α-skeletal actin (HSA) promoter (19, 20). Bdnfflox/flox;HSA-Cre
mice (hereafter referred as muscle knockout [MKO]) were born
at Mendelian ratios and exhibited an average lifespan comparable
with their Bdnfflox/flox control (CTRL) littermates (CTRL: 833.1 ±
38.2 d vs. MKO: 880 ± 31.3 d; n = 10 per genotype; not significant).
Significance
The brain-derived neurotrophic factor (BDNF) is essential to
promote neuronal differentiation, plasticity, and survival. Al-
tered BDNF expression is associated with several pathologies,
including neuropsychiatric and neurodegenerative disorders,
cardiovascular diseases, diabetes, and motor neuron diseases.
Although BDNF has been identified as a contraction-induced
myokine, its involvement in muscle physiology is unclear. Using
functional, cellular, and molecular approaches, we report here
that the myokine BDNF regulates glycolytic muscle fiber-type
identity. Our findings warrant additional studies to determine
whether modulating the activity of BDNF represents an effec-
tive therapeutic strategy to delay or even prevent muscle wasting
disorders in which the function of glycolytic muscle fibers is
compromised (e.g., in Duchenne muscular dystrophy, muscle
insulin resistance).
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Analysis of Bdnf transcript expression in 3-mo-old MKO mice
revealed a ≤70% reduction in both oxidative and glycolytic
skeletal muscle (Fig. 1A and SI Appendix, Fig. S1A). Interestingly,
while TrkB levels were not affected by BDNF depletion, other
NTs, such as NT-3 and NT-4/5, show increased and decreased
transcript expression, respectively, in the glycolytic gastrocnemius
(GAS) muscle (SI Appendix, Fig. S1A). We, however, could not
reveal changes in circulating BDNF; the latter was undetectable in
mouse serum (SI Appendix, Fig. S1B) in agreement with previous
studies (21, 22). Because BDNF is associated with fatty acid oxi-
dation (17, 23, 24), we evaluated systemic and muscle metabolism
of mice lacking muscle BDNF in a broad manner. MKO mice did
not show an overt metabolic phenotype in terms of daily food
intake (CTRL: 3.43 ± 0.11 g vs. MKO: 3.17 ± 0.26 g; n = 5 to 6;
not significant), body, lean and fat mass, glucose tolerance, daily
body temperature, VO2 consumption, or energy substrate utili-
zation (respiratory exchange ratio [RER]), which were all not
significantly different from CTRL mice (SI Appendix, Fig. S1 C–I).
In line with unchanged whole-body lean mass, individual
weights of different oxidative and glycolytic muscles were in-
distinguishable in BDNF MKO mice (SI Appendix, Fig. S1E).
Basic histological evaluation of glycolytic tibialis anterior (TA)
muscle revealed normal muscle structure (Fig. 1B). Using a te-
lemetry system to record spontaneous, in-cage locomotion over a
10-d period, we observed that nighttime general locomotor ac-
tivity was significantly reduced in MKO mice (Fig. 1C). A more
detailed characterization of locomotor and gait behavior using
the CatWalk XT system indicated that MKO gait velocity was
slightly reduced as supported by parameters associated with walk-
ing speed (Fig. 1D). Overall, these data show that, even though
spontaneous locomotion and walking speed are reduced in MKO
mice, BDNF deletion is not linked to pathological changes in
whole-body metabolism, body composition, and muscle mass and
morphology.
Muscle-Specific BDNF Deletion Reduces Motor End Plate Volume in
the Extensor Digitorum Longus Muscle. The BDNF-TrkB signaling
pathway plays an essential role in the maturation and mainte-
nance of the developing mammalian motor unit (6, 8, 13, 25).
We thus investigated whether the locomotor phenotype of MKO
mice was associated with NMJ abnormalities. We first evaluated
the expression of transcripts playing a key role in the function
and maintenance of the neuromuscular synapse and observed a
significant reduction of the Muscle-specific Kinase (MuSK) and
its downstream regulator Docking Protein 7 (Dok7) in glycolytic
muscles of MKO mice (Fig. 2A and SI Appendix, Fig. S2A). Of
note, loss of MuSK abolishes synapse formation in mice (26).
However, a closer examination of MuSK expression in sub-
synaptic regions—where it is preferentially expressed at the
adult NMJ—did not reveal any significant reduction on BDNF
deletion (SI Appendix, Fig. S2A). Moreover, MuSK protein
showed a normal presence at synaptic sites, colocalizing with
AChR clusters as in CTRL muscle (SI Appendix, Fig. S2B).
Lastly, transcripts encoding for the α-and e-AChR subunits
were similarly enriched in the synaptic area of both genotypes
(SI Appendix, Fig. S2C), further suggesting that molecules in-
volved in NMJ maintenance are likely present at similar levels
in adult MKO vs. CTRL muscles. Incidentally, transcript levels
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Fig. 1. BDNF MKO mice show altered spontaneous gait behavior and locomotion. (A) Bdnf gene expression in CTRL and BDNF MKO tissues. Expression values
were determined by qPCR and normalized to Hprt. Data are shown as the average fold change ± SEM (n = 3 to 9 per genotype per tissue) relative to the
expression in CTRL set to 1. CB, cerebellum; DIA, diaphragm; FB, forebrain; H, heart. (B) Histology of CTRL and MKO TA muscles as determined by hematoxylin
and eosin staining. (Scale bar: 100 μm.) (C) Total gross locomotor activity (n = 15 per genotype, average of a 10-d period) and (D) gait locomotor parameters
(n = 8 per genotype) of CTRL and MKO animals. Results are expressed as mean ± SEM. Unpaired Student’s t test (A and D) and 2-way ANOVA followed by
Sidak’s multiple comparisons (C and D). *P < 0.05; **P < 0.01; ***P < 0.001.
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of Bdnf and TrkB were not enriched in microdissected synap-
tic regions of adult CTRL muscles (SI Appendix, Fig. S2D),
hinting at synaptic and extrasynaptic functions of this signaling
pathway.
We then examined the morphology of NMJs from the extensor
digitorum longus (EDL)—a fast-twitch muscle used in rapid
movements of hind limb digits—of CTRL and MKO animals by
confocal microscopy. We used synaptotagmin, a synaptic vesicle-
associated Ca2+ protein, as a presynaptic marker; α-bungarotoxin,
a selective and potent ligand for AChR, to visualize the post-
synaptic membrane; and an antineurofilament antibody to label
motor nerve axons. Knockdown of muscle BDNF did not im-
pair synapse structure in regard to presynaptic–postsynaptic
apposition (Fig. 2 B and C). Similarly, no evidence of increased
NMJ fragmentation and denervation was observed in MKO
mice, indicating that muscle BDNF is not essential to maintain
NMJ integrity (Fig. 2 D and E). Strikingly, however, lack of
muscle BDNF led to a significant reduction of the motor end
plate volume (Fig. 2F). Importantly, the reduction in NMJ vol-
ume was not associated with significant changes in the expression
of p75NTR and both full-length and truncated forms of TrkB and
TrkC in motor neurons and interneurons that lie in the lumbar
portion of the spinal cord (SI Appendix, Fig. S2 E–G). Moreover,
these receptors were not or only poorly detected in the GAS
muscle (SI Appendix, Fig. S2 E–G), in keeping with their low
expression levels postdifferentiation (16, 17, 27). In summary,
muscle-specific ablation of BDNF does not affect NMJ apposi-
tion and integrity but evokes a shift in motor end plate size that is
reminiscent of slow-type muscles (28).
Loss of BDNF Promotes Slow Contraction Velocity and Fatigue
Resistance. We next assessed whether the morphological and mo-
lecular changes in the NMJs of MKO animals had any functional
consequences on muscle contractile and fatigue properties and
neuromuscular transmission. We first performed in situ measure-
ments of TA muscle function in response to sciatic nerve stimu-
lation. MKO muscles produced similar twitch and tetanic force as
their CTRL counterparts (Fig. 3A, force frequency curve, and Fig.
3E, cross-sectional area [CSA]-normalized maximal twitch and
tetanic forces), in line with in vivo measures of grip strength (SI
Appendix, Fig. S2J). In contrast, time-to-peak tension and half-
relaxation time were significantly longer in MKO mice (Fig. 3 B–
D), indicating slower contraction velocities. Next, we studied force
production during a fatigue protocol consisting of intermittent
100-Hz tetanic stimulations. After 1 min of repeated stimulation,
contraction force started to drop faster in CTRL than in MKO TA
muscles and remained lower until the end of the fatigue proto-
col (Fig. 3F). Consistent with fatigue resistance, BDNF knockout
muscles recovered significantly faster than CTRL muscles,
returning to ∼95% of baseline peak force, while CTRL mus-
cles reached ∼84% of peak force 3 min after the fatigue pro-
tocol (Fig. 3F).







Fig. 2. Muscle-specific BDNF deletion reduces motor end plate size in the EDL muscle. (A) Gene expression in CTRL and BDNF MKO GAS muscles. Expression
values were determined by qPCR and normalized to Hprt. Data are shown as the average fold change ± SEM (n = 12 per genotype) relative to the expression
in CTRL set to 1. (B) Confocal microscopy images illustrating the apposition of both pre- and postsynaptic markers and the motor neuron innervation of EDL
NMJs from CTRL and MKO mice. (Scale bar: 20 μm.) Quantification of (C) pre- and postsynapse apposition, (D) NMJ innervation, and (E) NMJ fragmentation.
(F) NMJ volume distribution from CTRL and MKO EDL muscles (Materials and Methods has the number of NMJ analyzed per muscle per genotype). Results are
expressed as percentage (mean ± SEM; n = 4 per genotype). Unpaired Student’s t test (A, C, and E) and 2-way ANOVA followed by Sidak’s multiple com-
parisons (D and F). *P < 0.05; ***P < 0.001.







To complement the in situ nerve–muscle stimulation experi-
ments, we also evaluated in vivo evoked compound muscle ac-
tion potentials (CMAPs) in the GAS muscle in response to
supramaximal repetitive nerve stimulation using electromyogra-
phy (EMG) as described previously (28). CMAPs did not sig-
nificantly differ between genotypes over 15 consecutive stimuli at
5, 10, or 30 Hz (Fig. 3H). However, we found greater reductions
of CMAPs at 50- and 100-Hz stimulation in CTRL than in MKO
mice (Fig. 3 G and H and SI Appendix, Fig. S2I). Remarkably,
while CMAPs dropped by ∼10 and ∼20% at 50- and 100-Hz
stimulation, respectively, CMAPs reduction was completely ab-
sent after 4 stimulations in MKO mice (Fig. 3H). Lastly, to assess
whether the changes in muscle contractile properties of MKO
mice are associated with altered NMJ functionality, we evaluated
both spontaneous and evoked neurotransmitter release using the
levator auris longus (LAL)—a fast-twitch neck muscle—as de-
scribed previously (29). Ex vivo electrophysiological recordings
showed that the resting muscle membrane potential and both
miniature end plate potential amplitude and frequency remained
unaffected by muscle BDNF deletion (SI Appendix, Fig. S3 A and
B, representative traces, and Tables S1 and S2). Likewise, there
was no significant difference in the average amplitude of evoked
neurotransmitter release, quantum content, and time constants
between mouse groups (SI Appendix, Fig. S3 C and D and Table
S3). Furthermore, short-term plasticity was indistinguishable
between LAL NMJ synapses of CTRL vs. MKO animals (SI
Appendix, Fig. S3 E and F). Together, these results indicate that
glycolytic muscles lacking BDNF exhibit slower contractile
properties and higher fatigue resistance in the absence of altered
synaptic communication.
BDNF MKO Mice Show Improved Running Capacity. The change in
NMJ morphology and the altered contractility in situ and using
EMG collectively suggest a higher endurance performance. To
test this, we first evaluated spontaneous wheel-running activity in
both groups over a 7-d period. MKO mice exhibited a similar
increase and overnight distribution of wheel activity as their
CTRL littermates (SI Appendix, Fig. S4A). Because running
performance as elicited by forced treadmill differs in many as-
pects from spontaneous mouse wheel-running activity, we then
characterized the running capacity of MKO animals under dy-
namic treadmill exercise conditions. Untrained mice from both
genotypes first performed a forced maximal running capacity test
(i.e., VO2max test) consisting of a speed increment of 2 m every
2 min at 15° inclination until exhaustion. In this strenuous ex-
ercise challenge, both genotypes demonstrated similar energy
substrate utilization (RER) during the course of the experiment
(SI Appendix, Fig. S4B). Furthermore, despite slightly higher
VO2 consumption rates toward the end of the running exercise
session, muscle BDNF deletion did not significantly improve
maximal aerobic capacity (SI Appendix, Fig. S4 C and D).
Moreover, plasma lactate accumulation—a marker of muscle
metabolism and fatigue—was similar in both genotypes at
exhaustion (SI Appendix, Fig. S4E). Nevertheless, MKO mice
were able to run significantly longer than CTRL mice (713 vs.
519 m; n = 9 per genotype; P = 0.044) (SI Appendix, Fig. S4 G
and H). Incidentally, expression of exercise- and NT-related
genes in response to an acute bout of treadmill exercise as
described above was similar in the GAS muscle of both mouse
genotypes (SI Appendix, Fig. S4 I and J).
Mice that performed the VO2max test were then subjected to
an endurance-type protocol, during which animals ran from 20 to
100% of their maximal running speed. Evaluation of energy fuel
utilization and oxygen consumption, specifically at moderate
exercise intensities [i.e., 20 to 60% of maximal speed when
muscle fat oxidation is at its highest (30, 31)] did not reveal any
differences between genotypes (Fig. 4 A and B). Moreover,
blood lactate levels were similarly increased in both genotypes at
CTRL (50 Hz stim.) 10mv/D 1ms/D
MKO (50 Hz stim.)
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Fig. 3. Lack of BDNF promotes slow muscle contraction and enhances fatigue resistance. (A) In situ TA absolute muscle force frequency relationship as
evoked by electrical sciatic nerve stimulation from CTRL (n = 4) and MKO (n = 5) mice. (B) Representative traces of twitch force from both genotypes. (C) Time-
to-peak tension and (D) half-relaxation time. (E ) CSA-normalized maximal twitch and tetanic forces. (F ) Average curves showing the force decline during a
4-min muscle fatigue protocol and of muscle force recovery up to 3 min after fatigue. (G) Representative EMG traces from CTRL (Upper) and MKO (Lower) GAS
muscle on 50-Hz stimulation of the sciatic nerve. (H) Average decrement in the amplitude of GAS CMAPs from 1st to 4th stimulation (5- to 50-Hz stimulation:
n = 9 to 10 per genotype; 100-Hz stimulation: n = 6 per genotype). Results are expressed as percentage. Unpaired Student’s t test (C–E) and 2-way ANOVA
followed by Sidak’s multiple comparisons (A, F, and H). *P < 0.05; **P < 0.01; ***P < 0.001.
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exhaustion (Fig. 4C). Conversely, blood glucose values were
significantly lower in MKO mice at exhaustion (Fig. 4D), which
could result from their altered performance. Indeed, in line with
their improved maximal running capacity, BDNF MKO animals
demonstrated significantly greater endurance performance, run-
ning about 1.5 times the distance of CTRL mice (BDNF MKO:
2,708 m; CTRL: 1,862 m; P = 0.015) (Fig. 4 F and G). In sum-
mary, deletion of BDNF in mouse skeletal muscle confers greater
resistance to fatigue during physical exercise without signifi-
cantly affecting whole-body aerobic capacity and energy substrate
utilization.
Lack of Muscle BDNF Promotes a Fast-to-Slow Transition in Glycolytic
Muscles. Muscle fiber type and oxidative capacity are essential
determinants of muscle contractile properties, endurance, and
fatigue (32). Therefore, we assessed whether BDNF deletion was
associated with a muscle fiber transformation. Fiber composition
and CSA were unchanged in the oxidative soleus (SOL) muscle
of MKO mice (SI Appendix, Fig. S5 A–C). In contrast, the pro-
portion of type IIX fibers in both glycolytic TA and EDL muscles
was significantly increased in MKO animals at the expense of
type IIB fibers (Fig. 5 A and B). Importantly, type IIX fibers
show characteristics intermediate to types IIA and IIB fibers (e.g.,
in terms of contraction velocities and resistance to fatigue as
evaluated above) and succinate dehydrogenase activity—a mi-
tochondrial enzyme involved in oxidative phosphorylation (33).
Accordingly, we observed that muscles depleted of BDNF
showed higher succinate dehydrogenase (SDH) activity-
dependent staining (Fig. 5C). Of note, the higher proportion
of type IIX fibers in both TA and EDL muscles of MKO mice
was not associated with significant change in myofiber CSA
(Fig. 5D).
To investigate whether other fiber type-specific genes were
also affected by this transition from type IIB to IIX, we measured
the expression of several key oxidative and glycolytic markers by
qPCR. In line, the α-cardiac form of the actin gene (Actc1)—a
major constituent of the contractile apparatus predominantly
expressed in oxidative muscles (34)—was elevated in the absence
of BDNF (Fig. 5E). Conversely, the glycolytic marker troponin-C
fast (Tnnc2) and transcriptional regulators controlling glycolytic
fiber identity, such as Baf60c/Smarcd3 (35) and Tbx15 (36), were
down-regulated in MKOs (Fig. 5E). The higher proportion of
type IIX fibers was, however, not associated with elevated ex-
pression of Ppargc1b (37) or increased mitochondrial transcript
and mitochondrial DNA levels (SI Appendix, Fig. S5D). We also
examined the level of transcripts encoding key sarcoplasmic
calcium-regulatory proteins in muscles of MKO mice. In par-
ticular, the fast-type calcium-transporting ATPase Atp2a1 (also
called sarco/endoplasmic reticulum Ca2+-ATPase 1 [Serca1]) was
reduced, while the slow-type form Atp2a2 (Serca2) was signifi-
cantly increased (Fig. 5F). In contrast, both the fast-type calse-
questrin 1 (Casq1) and the slow-type Casq2 were elevated in the
MKO animals (Fig. 5F). Additional transcripts encoding for
regulators of fast fiber Ca2+ homeostasis (e.g., myoregulin [Mrln]—
a repressor of SERCA activity expressed in fast fibers [38]—and
ryanodine receptor [RyR1] and parvalbumin [Pvalb]—highly
expressed in fast-contracting fibers that have a more developed
sarcoplasmic reticulum [33]) equally showed significantly re-
duced expression levels in muscle cells depleted of BDNF (Fig.
5F). These results collectively demonstrate that muscle-derived
BDNF depletion promotes a fast-to-slow transition in glycolytic
muscles.
BDNF Overexpression Increases Fast-Type Gene Expression and
Glycolytic Fibers. The effect of muscle BDNF deletion on fiber-
type composition prompted us to investigate the consequence of
enhanced BDNF expression in skeletal muscle of adult CTRL
mice. To this aim, a plasmid-based gene delivery method was
used to introduce either BDNF or an empty vector (EV) into the
TA muscle by electroporation. SI Appendix, Fig. S6A depicts in
vivo transfection efficiency of a pCAG-EGFP (enhanced green
fluorescent protein) expression vector using our established pa-
rameters, demonstrating even muscle distribution of EGFP at
7 and 21 d postelectroporation. Importantly, when TA muscles
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Fig. 4. BDNF MKO mice show improved running endurance capacity. (A) RER and (B) O2 consumption as a function of speed in CTRL and MKO animals during
endurance exercise challenge. Note that data in A and B are only depicted until a speed of 22 m/min (i.e., 60% of maximum speed). (C) Blood lactate and (D)
glucose levels at rest and within 1 min after exhaustion. (E) Maximal O2 consumption at exhaustion. (F) Maximal speed and (G) total distance reached at
exhaustion. Results are expressed as mean ± SEM (n = 9 per genotype except in A, B, and E, where data from 1 CTRL and 1 MKO mouse could not be included
due to O2 artifacts during run acquisition). Unpaired Student’s t test (E–G) and 2-way ANOVA followed by Sidak’s multiple comparisons (C and D). *P < 0.05;
**P < 0.01; #Significant difference (P < 0.05) between experimental conditions.







from CTRL mice were transfected with a BDNF-encoding vec-
tor, both pro- and mature forms of BDNF were detected 21 d
after electrotransfer with 2 different antibodies (Fig. 6A). This
clearly indicates that—alongside the drastic elevation of its
transcript (Fig. 6B)—BDNF is further processed and cleaved in
adult skeletal muscle.
Next, we found that BDNF elevation mirrored the conse-
quences of BDNF deletion at the gene expression level. Specif-
ically, there was a greater expression of glycolytic markers (e.g.,
Serca1 and its coregulator Mlrn) and of transcriptional mediators
of fast fiber-type gene programs, such as Baf60c and Tbx15 (Fig.
6 B and C). Because electroporation is known to produce significant
damage in skeletal muscle leading to satellite cell activation and the
formation of new fibers (39–41), we concomitantly determined
myosin heavy-chain composition in both small new fibers (i.e., based
on a CSA value < 20 μm2), nearly absent in nonelectroporated TA
muscle (Fig. 5D), and in larger fibers (CSA > 20 μm2) of EV- and
BDNF-electroporated muscles (Fig. 6D). Intriguingly, on BDNF
overexpression, small myofibers had a significantly lower content of
the type IIX myosin heavy-chain isoform alongside an elevation of
the type IIB isoform (Fig. 6E). Thus, overexpression of BDNF is
sufficient to induce fast-twitch markers and influence fiber-type
composition in skeletal muscle.
Higher Muscle Mass, Strength, and Oxidative Fibers in Old BDNF MKO
Mice. NMJ structure, muscle fiber type and contractile proper-
ties, fatigue resistance, and exercise capacity are all changed in
young adult BDNF MKO animals. Incidentally, altered NT sig-
naling at the neuromuscular interface is associated with the age-
related decline of muscle mass and function (15, 16, 42).
Moreover, there is an age-dependent decrease of both circulat-
ing BDNF and brain TrkB levels in humans (43, 44) and a
likewise age-dependent reduction of both Bdnf and TrkB levels
in the rodent brain (45–47). However, we could not find data on
muscle Bdnf and TrkB expression in the aging context and have,
therefore, compared their transcript levels in 6- vs. 24-mo-old
CTRL animals. We did not find any change in regard to Bdnf
and TrkB expression in the old muscle (Fig. 7A).
In a last set of experiments, we evaluated whether the lifelong
deletion of muscle BDNF would further alter muscle physiology
TA-EDL CTRL TA-EDL MKO






Fig. 5. Lack of BDNF leads to a type IIB to IIX transition in glycolytic muscles. (A) Representative fluorescence microscopy images illustrating the fiber-
type composition in the TA-EDL muscle of CTRL and MKO animals. Corresponding color legend for fiber types: type I = red, type IIA = blue, type IIX = unstained
(black), type IIB = green, and laminin = white. (Scale bar: 200 μm.) (B) Quantification of fiber-type content in (Left) TA and (Right) EDL muscles (n = 5 per ge-
notype). Note that EDL and TA muscles were analyzed separately. (C) Representative SDH staining of TA-EDL muscles from different CTRL and MKO animals.
(Scale bar: 500 μm.) (D) CSA based on minimal Feret’s diameter of (Left) TA and (Right) EDL myofibers (n = 5 per genotype). Results are expressed as percentage
(mean ± SEM). (E and F) Gene expression in CTRL and BDNF MKO GAS muscles. Expression values were determined by qPCR and normalized to Hprt. Data are
shown as the average fold change ± SEM (n = 12 per genotype) relative to the expression in CTRL set to 1. Unpaired Student’s t test (E and F) and 2-way ANOVA
followed by Sidak’s multiple comparisons (B and D). *P < 0.05; **P < 0.01; ***P < 0.001.
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in the aging context. Motor balance and coordination were un-
changed in 24-mo-old MKO mice (Fig. 7 B and C). Likewise, old
MKO animals demonstrated a running capacity comparable
with their CTRL littermates (Fig. 7D). Old MKO mice, how-
ever, showed significantly higher grip strength in comparison
with old CTRL mice (Fig. 7E). This was, furthermore, associ-
ated with significantly increased whole-body lean mass along-
side elevated GAS and quadriceps hind limb muscle mass (Fig.
7 F and G). Finally, we found a higher SDH activity-dependent
staining and a significantly increased proportion of type IIA
fibers in TA muscles of 24-mo-old MKO mice (Fig. 7 H and I).
Overall, these results suggest that lifelong expression of muscle
BDNF is not required for the maintenance of neuromuscular
function and that, conversely, the more oxidative phenotype of
muscles lacking BDNF contributes to attenuation of some aspects
of muscle aging.
Discussion
The trophic activity of BDNF and related NT family members is
well recognized in the interaction between cells of the central
nervous system (24, 48). In contrast, the regulation and function
of BNDF in other cell types remains less understood. Here, we
describe a hitherto unknown and surprising effect of skeletal
muscle BNDF on the promotion of a fast-twitch glycolytic muscle
fiber program using both loss- and gain-of-function approaches
in vivo.
Our findings uncover BDNF as a myokine that promotes a
glycolytic fiber phenotype; other factors, such as the insulin-like
growth factor 2 (IGF2), have been associated with embryonic
development of fast fibers (49), while IGF1 primarily promotes
hypertrophy of fibers, with minimal effects on fiber-type distri-
bution (50). In contrast, our data demonstrate that BDNF affects
the gene program and fiber composition of glycolytic muscles
without significantly altering muscle fiber CSA. It is, therefore,
conceivable that BNDF cooperates with other factors (e.g.,
IGF1) in the adaptation of skeletal muscle to resistance training.
Of note, the seemingly beneficial effect of muscle-specific de-
letion of BDNF on different parameters (e.g., fatigue resistance
and endurance capacity) might be offset in other contexts. It
thus will be interesting to test the performance of the BDNF
MKO animals in other paradigms where adequate function of
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Fig. 6. BDNF influences skeletal muscle fiber-type specification. (A) Expression of BDNF protein in EV- and BDNF-electroporated TA muscles (n = 5 per
condition) as determined by western blot. Note that muscle protein extracts from MKO animals were used as negative controls. (B and C) Gene expression in
EV- and BDNF-electroporated TA muscles. Expression values were determined by qPCR and normalized to Hprt. Data are shown as the average fold change ±
SEM (n = 5 per condition) relative to the expression in EV set to 1. (D) CSA based on minimal Feret’s diameter of TA myofibers (n = 5 per genotype). (E) Fiber-
type composition in small (Left) vs. large (Right) TA fibers (n = 5 per genotype). Results are expressed as percentage (mean ± SEM). Unpaired Student’s t test (B
and C) and 2-way ANOVA followed by Sidak’s multiple comparisons (E). *P < 0.05; **P < 0.01.







exercise performance). Nevertheless, other pathological set-
tings could profit from a reduction or ablation of muscle BNDF
as evidenced by the improvement of lean mass, muscle weight,
and grip strength in old mice.
Contrary to postnatal and whole-body disruption of TrkB (6,
15, 25), muscle-specific BDNF deletion did not adversely affect
neuromuscular structure and function. Furthermore, even
though we did not directly assess NMJ morphology and func-
tionality in old MKO animals, the fact that these mice displayed
similar, if not greater, muscle force, motor balance, and co-
ordination likely rules out an essential role for postsynaptic
BDNF expression in the lifelong maintenance of the motor
unit. Finally, our observations of unchanged substrate utiliza-
tion on BDNF deletion are contrasting with the proposed role
of BDNF as an exercise-induced myokine to regulate fatty acid
oxidation (17). Whether this difference stems from diverging
effects of long-term deletion (these results) vs. the transient
overexpression and the relatively modest induction of BDNF
after acute exercise bouts (17) remains unclear. In any case, in
contrast to its key function in other central and peripheral
cells controlling energy homeostasis (23, 24), BDNF depletion
did not alter systemic energy homeostasis. One limitation of
this study, however, is the use of the HSA-Cre transgene to
excise BDNF, leading to Cre expression from E9.5 in somitic
cells committed to the myogenic lineage (19, 20). It thus would
be interesting to initiate muscle BDNF deletion at a later stage
to rule out the possibility of any developmental compensa-
tion (51).
Some of the characteristics of muscle lacking BDNF (e.g.,
higher SDH activity, slower contraction and relaxation times,
and decreased fatigability rate) are found in endurance-trained
muscle (52). However, MKO mice did not show increased
spontaneous locomotor activity but rather, showed decreased
spontaneous locomotor activity—as some other mouse models
CTRL 1
MKO 1
CTRL 2 CTRL 3
MKO 2 MKO 3




Fig. 7. The 24-mo-old BDNF MKO mice show higher muscle mass, grip strength, and oxidative fiber number. (A) Gene expression in young (n = 6 per ge-
notype) and old (n = 7 to 9 per genotype) CTRL and BDNF MKO GAS muscles. Expression values were determined by qPCR and normalized to Hprt. Data are
shown as the average foldchange ± SEM relative to the expression in young CTRL set to 1. (B) Balance beam (CTRL n = 9, MKO n = 11), (C) rotarod (CTRL n = 9,
MKO n = 12), and (D) treadmill running data (CTRL n = 8, MKO n = 9). (E) Absolute and body mass-normalized forelimb muscle strength as determined by grip
test (CTRL n = 9, MKO n = 12). Note that experiments were performed from the age of 23 mo and that some mice from this specific cohort spontaneously died
between the start of our behavioral investigation and their euthanasia. (F) Normalized lean and fat mass and (G) absolute vs. normalized muscle mass from
24-mo-old CTRL (n = 7) and MKO (n = 9) animals just before euthanasia. QUAD, quadricep. (H) Representative SDH staining of TA muscles from different old
CTRL and MKO animals. Note that sections with the same number originate from the same slide. (Scale bar: 500 μm.). (I) Evaluation of TA muscle fiber
composition of old CTRL and MKO animals (n = 6 per genotype from randomly chosen muscles). Results are expressed as mean ± SEM. Unpaired Student’s
t test (B–E) and 2-way ANOVA followed by Sidak’s multiple comparisons (A, F, G, and I). *P < 0.05; **P < 0.01; ***P < 0.001; ##Significant difference (P < 0.01)
between conditions.
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exhibiting a slow-type muscle transition (36, 53)—ruling out
physical activity as a primary cause of the fiber-type change. In-
triguingly, there is a clear relationship between the expression of
the fast IIB myosin isoform and BDNF during early postnatal
development, when muscles are subjected to distinct programs of
myosin isoform transitions influenced, for example, by functional
demand or motor innervation (33, 54). For instance, the fast IIB
myosin isoform rises in both mouse EDL and GAS muscles from
day 5 until day 90 after birth (54). BDNF protein also gradually
increases in glycolytic muscles of rodent neonates but not in the
SOL (27, 55). Besides, combined administration of a ciliary
neurotrophic factor (CNTF)–BDNF mixture after neonatal sci-
atic nerve crush injury can rescue a small fraction (i.e., 5%) of type
IIB fibers in the EDL muscle (27). Mechanistically, it is not clear
how BNDF controls the type IIB fiber program. Future studies will
aim at elucidating the BDNF-activated signaling pathways that
ultimately result in a transcriptional induction of Baf60c and
Tbx15, 2 transcriptional regulators involved in fast-twitch
muscle-specific gene expression (35, 36). BDNF might also
affect these regulators indirectly [e.g., by modulating the ac-
tivity of the TrkB receptors present in nerve terminals of mo-
tor neurons (5, 6)] to mediate morphological remodeling of
the NMJ. In that regard, other approaches to overexpress
BDNF [e.g., the tetracycline-inducible system (56)] could not
only circumvent the significant changes induced by muscle
electroporation but also, allow the careful functional and
structural evaluation of the effect of muscle BDNF elevation at
different developmental stages on the neuromuscular system.
Finally, the role of extrinsic signals, such as muscle-derived
BDNF, in influencing the commitment of myoblast nuclei to
particular gene expression programs and thus, the differentia-
tion of these cells into slow vs. fast myofibers needs additional
investigation (Fig. 8).
In summary, we report here that BDNF is a myokine that
regulates glycolytic muscle fiber-type identity. Muscle-specific
loss of BDNF confers beneficial effects on endurance and miti-
gates loss of muscle mass and function in sarcopenia. Thus,
strategies aimed at neutralizing muscle BDNF might be of in-
terest in certain pathologies. Inversely, our findings of BNDF to
promote type IIB fiber programs could be leveraged in diseases
where the function of glycolytic muscle fibers is compromised
or increased fast-twitch muscle fiber activity is desirable. For
example, circulating BDNF levels are associated with type
2 diabetes (16, 57, 58), and chronic BDNF administration en-
hances glucose uptake in muscle cells (59), which could be, at
least in part, mediated by a higher proportion of glycolytic type
IIB muscle fibers. Moreover, BDNF may also modulate the
glycolytic capabilities of muscle fibers by mechanisms similar to
the fibroblast growth factor 21 myokine (60, 61). Lastly, in light
of the susceptibility of certain muscle fibers to muscle diseases
[e.g., Duchenne muscular dystrophy (62)] and the positive ef-
fect of essential determinants of fiber identity on muscle dis-
ease progression (63, 64), our findings warrant additional
studies to determine whether modulating the activity of BDNF
represents an effective therapeutic strategy to delay or even
prevent muscle wasting disorders.
Materials and Methods
Animals. HSA-Cre transgenic mice were purchased from the Jackson Lab-
oratory (stock no. 006149). Bdnfflox/flox mice were a gift from Yves-Alain
Barde, Cardiff University, Wales, United Kingdom and have been pre-
viously characterized (ref. 65 has mutation and genotyping details). Mice
were maintained on a C57BL/6J genetic background in the animal facility
of the Biozentrum (University of Basel) in a temperature-controlled room
(21 °C to 22 °C) under a 12:12-h light/dark cycle (lights on at 6:00 AM).
Unless specifically mentioned, all experiments were performed in young
adult male mice (3 to 4 mo old) housed in groups of 3 to 5 in standard
cages with enrichment and free access to regular chow diet (3432; KLIBA
NAFAG) and water. All experiments were performed in accordance with
the principles of the Basel Declaration and with Federal and Cantonal
Laws regulating the care and use of experimental animals in Switzerland
as well as institutional guidelines of the Biozentrum and the University of
Basel. The protocol with all methods described here was approved by the
Kantonales Veterinäramt of the Kanton Basel-Stadt under consideration
of the wellbeing of the animals and the 3R (replacement, reduction, and
refinement) principle.
Statistical Analysis. No statistical methods were used to predetermine
sample size. The n number used per genotype for each experiment is
indicated in the figure legends. Data are expressed as mean ± SEM and
were represented and analyzed with the GraphPad Prism 7.0 software.
Comparisons between 2 groups were performed with unpaired Student’s
t test. For assessment between 2 independent variables, 2-way ANOVA
was used followed by Sidak’s multiple comparisons test if the interaction
term was significant. A value of P < 0.05 was considered statistically
significant. Symbols used to indicate the different degrees of statistical
significance are as follow: *P < 0.05, **P < 0.01, and ***P < 0.001 between
mouse genotypes and #P < 0.05 and ##P < 0.01 between experimental
conditions.
Details about body composition analysis; comprehensive laboratory ani-
mal monitoring system, glucose homeostasis, body temperature and loco-
motor activity recordings, gait analysis, indirect calorimetry coupled to
treadmill exercise, repetitive nerve stimulation EMG, muscle force and fa-
tigue measurements, muscle electroporation, tissue collection, enzyme-
linked immunosorbent assay, histology and immunohistochemistry, slide
imaging and image analysis, muscle RNA extraction and real-time qPCR,
protein extraction and western blot, mitochondrial DNA number, laser
capture microdissection, electrophysiology, behavioral phenotyping of old
mice, and antibodies and reagents are provided in SI Appendix, Supple-
mentary Materials and Methods. Primer pairs and TaqMan probes used in
this study are listed in SI Appendix, Table S4.
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Fig. 8. Proposed model by which BDNF signaling regulates neuromuscular
physiology. (1) BDNF could act as an autocrine factor to influence the ex-
pression of transcriptional regulators involved in fast-twitch muscle-specific
gene expression or the expression of synaptic proteins involved in AChR
clustering. (2) As a paracrine factor, BDNF could regulate the differentiation
of satellite cells into slow vs. fast myofibers. (3) BDNF might also affect
myofiber identity and motor end plate structure indirectly (e.g., by modu-
lating the activity of the TrkB receptors present in nerve terminals of motor
neurons).
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